[go: up one dir, main page]

AU6152000A - Copolymers for the transfer of nucleic acids to the cell - Google Patents

Copolymers for the transfer of nucleic acids to the cell

Info

Publication number
AU6152000A
AU6152000A AU61520/00A AU6152000A AU6152000A AU 6152000 A AU6152000 A AU 6152000A AU 61520/00 A AU61520/00 A AU 61520/00A AU 6152000 A AU6152000 A AU 6152000A AU 6152000 A AU6152000 A AU 6152000A
Authority
AU
Australia
Prior art keywords
copolymers
cell
transfer
nucleic acids
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61520/00A
Inventor
Dirk Finsinger
Christian Plank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU6152000A publication Critical patent/AU6152000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AU61520/00A 1999-06-25 2000-06-23 Copolymers for the transfer of nucleic acids to the cell Abandoned AU6152000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99112260A EP1063254A1 (en) 1999-06-25 1999-06-25 Copolymers for the transport of nucleic acids in the cell
EP99112260 1999-06-25
PCT/EP2000/005869 WO2001000709A1 (en) 1999-06-25 2000-06-23 Copolymers for the transfer of nucleic acids to the cell

Publications (1)

Publication Number Publication Date
AU6152000A true AU6152000A (en) 2001-01-31

Family

ID=8238431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61520/00A Abandoned AU6152000A (en) 1999-06-25 2000-06-23 Copolymers for the transfer of nucleic acids to the cell

Country Status (6)

Country Link
EP (2) EP1063254A1 (en)
JP (1) JP2003503569A (en)
AU (1) AU6152000A (en)
CA (1) CA2377211A1 (en)
MX (1) MXPA01012802A (en)
WO (1) WO2001000709A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300380B2 (en) 2002-12-30 2008-11-06 Nektar Therapeutics Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
JP4535229B2 (en) 2003-05-08 2010-09-01 国立大学法人 東京大学 Polyethylene glycol-polycation block copolymer
JP2005080598A (en) * 2003-09-10 2005-03-31 Japan Science & Technology Agency Method for introducing plasmid DNA using β-1,3-glucan derivative
JPWO2005078084A1 (en) * 2004-02-13 2008-01-10 株式会社東京大学Tlo Polyion complex carrying double-stranded oligonucleic acid, process for producing the same and pharmaceutical composition containing the same
JP4870941B2 (en) * 2005-05-09 2012-02-08 公立大学法人大阪府立大学 High molecular compound
DE102005023993A1 (en) * 2005-05-20 2006-11-23 TransMIT Gesellschaft für Technologietransfer mbH Non-viral vector system for the transport of nucleic acid into the lung
EP1979407B1 (en) * 2006-01-19 2014-08-06 Allexcel, Inc. Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers
CN101636169B (en) * 2007-01-22 2014-05-07 阿列克斯塞尔公司 Self-assembling amphiphilic polymers as antiviral agents
KR101470679B1 (en) * 2007-07-19 2014-12-08 올엑셀, 인크. Self-assembling amphiphilic polymers as anticancer agents
CN111727049A (en) 2017-12-07 2020-09-29 阿道恰公司 An injectable solution at pH 7 comprising at least one basal insulin with a PI between 5.8 and 8.5 and a copolyamino acid with a carboxylate charge and a hydrophobic group
TW201938190A (en) 2017-12-07 2019-10-01 法商阿道洽公司 Injectable solution at PH 7 comprising at least one basal insulin wherein the PI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
CA2146990A1 (en) * 1992-10-14 1994-04-28 Robert A. Snow Chelating polymers
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
JP3808938B2 (en) * 1996-07-16 2006-08-16 久光製薬株式会社 Nucleic acid carrier
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
KR20010071279A (en) * 1998-05-20 2001-07-28 추후제출 A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier

Also Published As

Publication number Publication date
CA2377211A1 (en) 2001-01-04
JP2003503569A (en) 2003-01-28
MXPA01012802A (en) 2003-06-24
WO2001000709A1 (en) 2001-01-04
EP1208133A1 (en) 2002-05-29
EP1063254A1 (en) 2000-12-27

Similar Documents

Publication Publication Date Title
AU4501901A (en) Heat transfer delay
HUP0001937A3 (en) Compounds, preparation and use for transferring nucleic acids into cells
AU5768000A (en) Personal cervical cell collector
AU6788100A (en) Liquid array technology
AU6629200A (en) Alpha-helical peptide nucleic acid alpha-pna
AU1410399A (en) Nucleic acid transfer vector for the introduction of nucleic acid into the dna of a cell
AU1115200A (en) Nucleic acid arrays
PL358811A1 (en) High order nucleic acid based structures
AU6152000A (en) Copolymers for the transfer of nucleic acids to the cell
AU2576100A (en) Novel enzyme
AU6611500A (en) Single-phase amplification of nucleic acids
AU2001289943A1 (en) Complexes for transferring nucleic acids into cells
AU5061000A (en) Novel glucoamylase
AU1380001A (en) Heat accumulator
AU7691700A (en) Charnel system having independently divided cells
AU2421301A (en) Material transfer system
AU5276000A (en) Universal solid supports suitable for the synthesis of nucleic acids
AU7318700A (en) Novel transaldolase gene
AU1035901A (en) Transfer system
AU1029099A (en) Transfection system for the transfer of nucleic acids into cells
AU5377599A (en) Nucleic acids
AU5590999A (en) Peptide scaffolds for transfer of molecules into eukaryotic cells
AU4367900A (en) Carbohydrate-modifying enzymes
AU5852000A (en) Atopy gene
AU1461397A (en) Rapid assay to estimate gene transfer into cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase